Sign in
Active, not recruitingPhase 3

MAD Trial: Myopia Atropine Dose

Key facts

Who runs it
Erasmus Medical Center
Where
Netherlands21 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
550 people, planned
Started
19 Dec 2022
Expected to end
24 Apr 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Atropine Ophthalmic 0.05%
  • Atropine Ophthalmic 0.5%
Record updated
14 September 2026

Who can take part

Age
6 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Children aged 6 to ≤ 11 years with bilateral myopia
  • Onset of myopia ≥ 4 years of age
  • History of progression
  • SER of at least -1.00D and no greater than -6.00D in each eye measured using cycloplegic auto refraction
  • Intraocular pressure < 21 mm Hg in each eye
  • Distance vision correctable to at least 0.1 Log MAR (logarithm of the minimum angle of resolution) in each eye

Who cannot take part

  • Chronic use of topical or systemic antimuscarinic/anticholinergic medications in the 21 days prior to screening, and/or anticipated need for chronic use over the duration of the study (i.e., more than 7 consecutive days in 1 month or more than a total of 30 days in 1 year)
  • Chronic use (more than 3 days a week) of topical ophthalmological medication (prescribed or over the counter) other than the assigned study medication. The use of artificial tears is allowed but not in the 1 hour before or after the administration of the study medication
  • The anticipated need to use chronic ophthalmic or systemic oral corticosteroids during the study. (i.e., < 2 weeks)
  • Prior myopia treatments
  • Allergy to atropine or other excipients of the eye drops
  • History of amblyopia or strabismus
  • History of retinal dystrophy or systemic disorder
  • History of glaucoma
  • Abnormal ocular biometry aside from axial length
  • Employees of the study center and their family members

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.

The 2 groups in the trial

  • Low dose atropineExisting treatment, for comparison

    Atropine 0.05% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.

    Treatment: Atropine Ophthalmic 0.05%

  • High dose atropineExisting treatment, for comparison

    Atropine 0.5% sulphate ophthalmic solution should be administered, one drop in each eye, once daily, at bedtime, for 3 years.

    Treatment: Atropine Ophthalmic 0.5%

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Investigator Led, Double-masked, Multicenter, Randomized Clinical Trial for the Comparison of Atropine 0.5% Versus Atropine 0.05% Eye Drops for the Prevention of Myopia Progression in Dutch Children
Record updated
14 September 2026